罕见疾病的昂贵药物:“加拿大，我们这里有一个问题”。

Q3 Medicine

Healthcare Papers Pub Date : 2023-01-01 DOI:10.12927/hcpap.2023.27001

Joel Lexchin

{"title":"罕见疾病的昂贵药物:“加拿大，我们这里有一个问题”。","authors":"Joel Lexchin","doi":"10.12927/hcpap.2023.27001","DOIUrl":null,"url":null,"abstract":"This issue of Healthcare Papers on expensive drugs for rare diseases (EDRDs) is very timely. According to the recently released Patented Medicine Prices Review Board's 2021 annual report, EDRDs have gone from 1.7% of pharmaceutical expenditures in 2012 to 12.2% in 2021, with a compound annual growth rate between 2012 and 2021 of 31.7% compared to 6.0% for all prescription medicines (PMPRB 2022).","PeriodicalId":35522,"journal":{"name":"Healthcare Papers","volume":"21 1","pages":"4-8"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Expensive Drugs for Rare Diseases: \\\"Canada, We Have a Problem Here\\\".\",\"authors\":\"Joel Lexchin\",\"doi\":\"10.12927/hcpap.2023.27001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"This issue of Healthcare Papers on expensive drugs for rare diseases (EDRDs) is very timely. According to the recently released Patented Medicine Prices Review Board's 2021 annual report, EDRDs have gone from 1.7% of pharmaceutical expenditures in 2012 to 12.2% in 2021, with a compound annual growth rate between 2012 and 2021 of 31.7% compared to 6.0% for all prescription medicines (PMPRB 2022).\",\"PeriodicalId\":35522,\"journal\":{\"name\":\"Healthcare Papers\",\"volume\":\"21 1\",\"pages\":\"4-8\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Healthcare Papers\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.12927/hcpap.2023.27001\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Healthcare Papers","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12927/hcpap.2023.27001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

这期《罕见病昂贵药物卫生论文》非常及时。根据最近发布的专利药品价格审查委员会2021年年度报告，EDRDs已从2012年占药品支出的1.7%上升到2021年的12.2%，2012年至2021年的复合年增长率为31.7%，而所有处方药的复合年增长率为6.0% (PMPRB 2022)。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Expensive Drugs for Rare Diseases: "Canada, We Have a Problem Here".

This issue of Healthcare Papers on expensive drugs for rare diseases (EDRDs) is very timely. According to the recently released Patented Medicine Prices Review Board's 2021 annual report, EDRDs have gone from 1.7% of pharmaceutical expenditures in 2012 to 12.2% in 2021, with a compound annual growth rate between 2012 and 2021 of 31.7% compared to 6.0% for all prescription medicines (PMPRB 2022).

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Healthcare Papers Medicine-Health Policy

CiteScore

2.50

自引率

0.00%

发文量

期刊介绍： Integrating community-based health and social care has grabbed international attention as a way of addressing the needs of aging populations while contributing to health systems" sustainability. However, integrating initiatives in different jurisdictions work (or do not work) within very various.